Roche Holding (RHHBY)
(Delayed Data from OTC)
$40.40 USD
-0.21 (-0.52%)
Updated Oct 31, 2025 04:00 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RHHBY 40.40 -0.21(-0.52%)
Will RHHBY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for RHHBY
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Other News for RHHBY
Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window
VYMI: Foreign 4.3% Dividend Yield Made Cheap And Simple
FDA moves to accelerate biosimilar development, lower drug costs
FDA moves to accelerate biosimilar development, lower drug costs
Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback